Terms: = Kidney tumors AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9
28 results:
1. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract] [Full Text] [Related]
2. Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.
Prosz A; Duan H; Tisza V; Sahgal P; Topka S; Klus GT; Börcsök J; Sztupinszki Z; Hanlon T; Diossy M; Vizkeleti L; Stormoen DR; Csabai I; Pappot H; Vijai J; Offit K; Ried T; Sethi N; Mouw KW; Spisak S; Pathania S; Szallasi Z
Sci Rep; 2023 Nov; 13(1):20567. PubMed ID: 37996508
[TBL] [Abstract] [Full Text] [Related]
3. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
[TBL] [Abstract] [Full Text] [Related]
4. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Bergerot C; Young Rha S; Pal S; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Lyun Lee J; Sunela K; Ciuleanu T; Heng D; Glen H; Wang J; Bennett L; Pan J; O'Hara K; Puente J
Oncologist; 2023 Jan; 28(1):59-71. PubMed ID: 35881028
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of class II cystic renal masses proposed in Bosniak classification version 2019: a systematic review of supporting evidence.
McGrath TA; Shoeib A; Davenport MS; Silverman SG; McInnes MDF; Schieda N
Abdom Radiol (NY); 2021 Oct; 46(10):4888-4897. PubMed ID: 34152438
[TBL] [Abstract] [Full Text] [Related]
6. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent.
Yang ES; Nassar AH; Adib E; Jegede OA; Alaiwi SA; Manna DLD; Braun DA; Zarei M; Du H; Pal SK; Naik G; Sonpavde GP
Mol Cancer Ther; 2021 Aug; 20(8):1454-1461. PubMed ID: 34108261
[TBL] [Abstract] [Full Text] [Related]
7. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.
Bhanegaonkar A; Pandya S; Zheng Y; Kim R; Krulewicz S; Kasturi V; Phatak H
Adv Ther; 2021 May; 38(5):2644-2661. PubMed ID: 33866526
[TBL] [Abstract] [Full Text] [Related]
8. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity.
Hermansen CK; Donskov F
J Geriatr Oncol; 2021 Jun; 12(5):827-833. PubMed ID: 33388280
[TBL] [Abstract] [Full Text] [Related]
10. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
Götz TI; Lang EW; Prante O; Cordes M; Kuwert T; Ritt P; Ludwig B; Schmidkonz C
Nuklearmedizin; 2020 Sep; 59(5):365-374. PubMed ID: 32663888
[TBL] [Abstract] [Full Text] [Related]
11. Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma.
Pal SK; McDermott DF; Atkins MB; Escudier B; Rini BI; Motzer RJ; Fong L; Joseph RW; Oudard S; Ravaud A; Bracarda S; Suárez C; Lam ET; Choueiri TK; Ding B; Quach C; Hashimoto K; Schiff C; Piault-Louis E; Powles T
BJU Int; 2020 Jul; 126(1):73-82. PubMed ID: 32233107
[TBL] [Abstract] [Full Text] [Related]
12. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab
Atkins MB; Rini BI; Motzer RJ; Powles T; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Gurney H; Oudard S; Uemura M; Lam ET; Grüllich C; Quach C; Carroll S; Ding B; Zhu QC; Piault-Louis E; Schiff C; Escudier B
Clin Cancer Res; 2020 Jun; 26(11):2506-2514. PubMed ID: 32127394
[TBL] [Abstract] [Full Text] [Related]
13. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract] [Full Text] [Related]
14. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
[TBL] [Abstract] [Full Text] [Related]
15. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract] [Full Text] [Related]
16. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of
Zazuli Z; Otten LS; Drögemöller BI; Medeiros M; Monzon JG; Wright GEB; Kollmannsberger CK; Bedard PL; Chen Z; Gelmon KA; McGoldrick N; Kitchlu A; Vijverberg SJH; Masereeuw R; Ross CJD; Liu G; Carleton BC; Maitland-van der Zee AH
Genes (Basel); 2019 May; 10(5):. PubMed ID: 31083486
[TBL] [Abstract] [Full Text] [Related]
17. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
Cella D; Escudier B; Tannir NM; Powles T; Donskov F; Peltola K; Schmidinger M; Heng DYC; Mainwaring PN; Hammers HJ; Lee JL; Roth BJ; Marteau F; Williams P; Baer J; Mangeshkar M; Scheffold C; Hutson TE; Pal S; Motzer RJ; Choueiri TK
J Clin Oncol; 2018 Mar; 36(8):757-764. PubMed ID: 29377755
[TBL] [Abstract] [Full Text] [Related]
18. The polymorphism XRCC1 Arg194Trp and 8-hydroxydeoxyguanosine increased susceptibility to arsenic-related renal cell carcinoma.
Hsueh YM; Lin YC; Chen WJ; Huang CY; Shiue HS; Pu YS; Chen CH; Su CT
Toxicol Appl Pharmacol; 2017 Oct; 332():1-7. PubMed ID: 28733204
[TBL] [Abstract] [Full Text] [Related]
19. XRCC3 Thr241Met and xpd Lys751Gln gene polymorphisms and risk of clear cell renal cell carcinoma.
Loghin A; Bănescu C; Nechifor-Boila A; Chibelean C; Orsolya M; Nechifor-Boila A; Tripon F; Voidazan S; Borda A
Cancer Biomark; 2016; 16(2):211-7. PubMed ID: 26682510
[TBL] [Abstract] [Full Text] [Related]
20. [DNA repair XRCC1, xpd genes polymorphism as associated with the development of bladder cancer and renal cell carcinoma].
Akhmadishina LZ; Giliazova IR; Kutlyeva LR; Korytina GF; Kochetova OV; Urmantsev MF; Izmaĭlova SM; Izmaĭlov AA; Kunsbaeva GB; Zagidullin AA; Haliullin AA; Pavlov VN; Viktorova TV; Husnutdinova EK
Genetika; 2014 Apr; 50(4):481-90. PubMed ID: 25715450
[TBL] [Abstract] [Full Text] [Related]
[Next]
